April 30, 2019 — New data presented at the Society of Interventional Radiology (SIR) 2019 annual meeting showed the Ellipsys Vascular Access System was the preferred technique for performing endovascular AV fistula creation (endoAVF) compared to other approaches. Data on the U.S. Food and Drug Administration (FDA)-cleared device were presented by Robert Shahverdyan, M.D., head of the Vascular Access Center at Asklepios Klinik Barmbek in Hamburg, Germany.
Ellipsys, a minimally-invasive catheter-based system designed for end-stage renal disease (ESRD) patients requiring hemodialysis, provides physicians and patients access to a non-surgical option for AV fistula creation. In his presentation, Shahverdyan outlined the comparative benefits of using Ellipsys when compared to other available technology, including faster procedure time, no need for X-rays or contrast agents, and a simpler procedure to perform overall.
In addition to Shahverdyan’s presentation, another SIR 2019 study centered around the use of Ellipsys, titled “The Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation for Hemodialysis Access.” The study was led by Jeffrey H. Hull, M.D. of Richmond Vascular Center, and was selected by the editors of the Journal of Vascular and Interventional Radiology (JVIR) as the Outstanding Clinical Study of the Year, the society’s top award. Hull’s paper was chosen by JVIR editorial board members from among hundreds of reviewed manuscripts published in 2018 and singled out as the most essential, best-in-class research conducted in interventional radiology in the last year.
For more information: www.avenumedical.com
July 25, 2024 
